NCT03728556View on ClinicalTrials.gov

A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

381

Participants

Timeline

Start Date

October 26, 2018

Primary Completion Date

April 3, 2023

Study Completion Date

April 3, 2023

Conditions
Non-Small Cell Lung Cancer Stage III
Interventions
BIOLOGICAL

CS1001 monoclonal antibody

Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months

BIOLOGICAL

CS1001 placebo

Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months

Trial Locations (1)

510080

Guangdong Provincial People's Hospital, Guangzhou

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY

NCT03728556 - A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter